VX-166
WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#:510228
CAS#:800408-39-3
Description:VX-166 is a broad caspase inhibitor, which can be used as a novel potential treatment for sepsis. VX-166 reduces fibrosis in an animal model of nonalcoholic steatohepatitis.
Price and Availability
VX-166 is not in stock, but may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.
Chemical Structure
Theoretical Analysis
MedKoo Cat#: 510228Name: VX-166CAS#: 800408-39-3Chemical Formula: C22H21F4N3O8Exact Mass: 531.12648Molecular Weight: 531.41Elemental Analysis: C, 49.72; H, 3.98; F, 14.30; N, 7.91; O, 24.09
Synonym:VX166, VX 166, VX-166
IUPAC/Chemical Name:(S)-3-((S)-2-(3-((methoxycarbonyl)amino)-2-oxopyridin-1(2H)-yl)butanamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid
InChi Key:WQNDPVUOABHOHK-KBPBESRZSA-N
InChi Code:InChI=1S/C22H21F4N3O8/c1-3-14(29-6-4-5-12(21(29)34)28-22(35)36-2)20(33)27-13(8-16(31)32)15(30)9-37-19-17(25)10(23)7-11(24)18(19)26/h4-7,13-14H,3,8-9H2,1-2H3,(H,27,33)(H,28,35)(H,31,32)/t13-,14-/m0/s1
SMILES Code:O=C(O)C[C@H](NC([C@@H](N1C=CC=C(NC(OC)=O)C1=O)CC)=O)C(COC2=C(F)C(F)=CC(F)=C2F)=O
Technical Data
References
1: Collins JL, Peng X, Lee R, Witriol A, Pierre Z,Sciuto AM. Determination of LCt(50)s in anesthetized rats exposed toaerosolized nerve agents. Toxicol Mech Methods. 2013 Feb;23(2):127-33.doi: 10.3109/15376516.2012.730560. Epub 2012 Oct 19. PubMed PMID:22978758.
2: Anstee QM, Concas D, Kudo H, Levene A, Pollard J, Charlton P, ThomasHC, Thursz MR, Goldin RD. Impact of pan-caspase inhibition in animalmodels of established steatosis and non-alcoholic steatohepatitis. JHepatol. 2010 Sep;53(3):542-50. doi: 10.1016/j.jhep.2010.03.016. Epub2010 May 26. PubMed PMID: 20557969.
3: Weber P, Wang P, Maddens S, Wang PSh, Wu R, Miksa M, Dong W,Mortimore M, Golec JM, Charlton P. VX-166: a novel potent small moleculecaspase inhibitor as a potential therapy for sepsis. Crit Care.2009;13(5):R146. doi: 10.1186/cc8041. Epub 2009 Sep 9. PubMed PMID:19740426; PubMed Central PMCID: PMC2784364.
4: Witek RP, Stone WC, Karaca FG, Syn WK, Pereira TA, Agboola KM,Omenetti A, Jung Y, Teaberry V, Choi SS, Guy CD, Pollard J, Charlton P,Diehl AM. Pan-caspase inhibitor VX-166 reduces fibrosis in an animalmodel of nonalcoholic steatohepatitis. Hepatology. 2009Nov;50(5):1421-30. doi: 10.1002/hep.23167. PubMed PMID: 19676126.
5: Hilmas CJ, Poole MJ, Finneran K, Clark MG, Williams PT. Galantamineis a novel post-exposure therapeutic against lethal VX challenge.Toxicol Appl Pharmacol. 2009 Oct 15;240(2):166-73. doi:10.1016/j.taap.2009.07.029. Epub 2009 Jul 30. PubMed PMID: 19647007.
6: Sakurada K, Ikegaya H, Ohta H, Akutsu T, Takatori T. Hydrolysis of anacetylthiocholine by pralidoxime iodide (2-PAM). Toxicol Lett. 2006 Oct25;166(3):255-60. Epub 2006 Aug 12. PubMed PMID: 16971069.
7: Haberham ZL, van den Brom WE, Venker-van Haagen AJ, de Groot HN,Baumans V, Hellebrekers LJ. The rat vertex-middle latencyauditory-evoked potential as indicator of anaesthetic depth: acomparison with evoked-reflex testing. Brain Res. 2000 Aug11;873(2):287-90. PubMed PMID: 10930556.
8: Bosković B. The influence of 2-/o-cresyl/-4 H-1 : 3 :2-benzodioxa-phosphorin-2-oxide (CBDP) on organophosphate poisoning andits therapy. Arch Toxicol. 1979 Jul 11;42(3):207-16. PubMed PMID:475595.
